Introduction The prevalence of surgical site infection (SSI) remains higher in gastrointestinal surgery than in other surgeries. Although several guidelines have indicated the efficacy of chlorhexidine and povidone-iodine in reducing the SSI rate, the optimal recommendation has still not been established. Therefore, it is necessary to determine the more effective antiseptic for surgical site preparation. Olanexidine (1.5% olanedine, Otsuka Pharmaceutical Factory, Tokushima, Japan), which is a new antiseptic in Japan, has antimicrobial activity against a wide range of bacteria, including Gram-positive and Gram-negative bacteria. Our study will contribute to determining a new antiseptic for use in gastrointestinal and other surgeries.
Methods and analysis We propose a multicentre, randomised controlled clinical trial for comparing two treatments, that is, 1.5% olanexidine or 10% povidone-iodine, for surgical skin preparation to prevent SSI in clean-contaminated gastrointestinal surgeries with surgical wounds. Patients aged ≥20 years at the time of consent will be included. The primary outcome measure is the 30-day postoperative SSI rate. For the primary analysis, which is aimed at comparing the treatment effects, the adjusted risk ratio and its 95% CI will be estimated using the Mantel-Haenszel method.
Ethics and dissemination The protocol was first approved by the Institutional Review Board of Keio University School of Medicine, followed by the institutional review board of each participating site. Participant recruitment began in June 2018. The final results will be published in international peer-reviewed medical journals.
Trial registration number UMIN 000031560; Pre-results.
- wound management
- gastrointestinal infections
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
Statistics from Altmetric.com
Contributors MT and HO contributed equally to this study. All authors made significant contribution to the conception and design of the study protocol. MT designed the study and wrote the protocol and manuscript. SM, TI, KF, RN, NW, MK, HY, YA, GO, SH, MT, TI, TY, KH, YI, YS, HH, YM, MS and TK assisted with the development of the study design and protocol. The protocol was reviewed by HO, HK, MS, KO and YK. YS wrote the statistical analysis plan. All authors gave final approval of the manuscript and agree to be accountable for all aspects of the work.
Funding This work was supported by donations from the Department of Surgery, Keio University School of Medicine and Ohyama Health Foundation Inc.
Disclaimer Otsuka Pharmaceutical Factory Inc. was not involved in the planning of the protocol or in the conduct of the trial.
Competing interests YK received grant support from Otsuka Pharmaceutical Factory Inc.
Ethics approval The protocol was first approved by the Institutional Review Board of Keio University School of Medicine and then approved by the institutional review board of each participating site.
Provenance and peer review Not commissioned; externally peer reviewed.
Patient consent for publication Not required.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.